INLYTA, generically known as axitinib, is a prescription medication primarily used in the treatment of advanced renal cell carcinoma (RCC), which is a type of kidney cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), which work by blocking certain proteins that promote tumor growth and spread. By inhibiting these proteins, INLYTA can slow down the progression of the cancer and may help to shrink the tumor. It is typically prescribed for patients who have not responded well to other cancer treatments. As with any medication, it is important for patients to discuss the potential benefits and risks of using INLYTA with their healthcare provider, as well as any possible side effects, which can include hypertension, fatigue, and gastrointestinal issues among others.